A diterpene is a terpenoid built from four isoprene units, giving a characteristic twenty-carbon (C20) framework biosynthesized from the linear precursor geranylgeranyl diphosphate.[1] Membership is defined structurally — by the carbon scaffold and its derivation from this precursor — rather than by any shared pharmacological target, which makes diterpene a broad chemical grouping whose members can act on entirely different biological systems.
The class spans many distinct scaffold families — labdane, clerodane, kaurane, taxane, grayanane, and others — each produced by a different diterpene synthase acting on the same C20 precursor.
Among the psychoactive and toxic members covered here are the neoclerodane salvinorin A, the active constituent of Salvia divinorum, and the grayanane polyol grayanotoxin from plants in the Ericaceae family. Both lack the basic nitrogen typical of most psychoactive compounds.
Beyond their shared chemistry these members behave very differently. Salvinorin A produces a brief, intense hallucinogenic and dissociative state, used ritually by Mazatec healers in Oaxaca and also encountered recreationally.[2] Grayanotoxin is not used recreationally; it reaches people incidentally through "mad honey" produced by bees foraging on Rhododendron flowers, acting as a cardiovascular toxin rather than a psychoactive substance.[3]
Pharmacology
The diterpene class has no shared pharmacological mechanism. Membership is structural, not functional, and the represented scaffolds reach their biological effects through entirely separate molecular machinery.[1]
| Scaffold | Representative member | Molecular target and route to effect |
|---|---|---|
| Neoclerodane | salvinorin A (from Salvia divinorum) | High-efficacy, high-selectivity agonist at the kappa-opioid receptor (KOR); couples to Gi/o, suppresses adenylyl cyclase and cAMP, and counter-modulates dopamine release in reward circuits[4] |
| Grayanane | grayanotoxin | Binds site II of voltage-gated sodium channels and prevents normal inactivation, producing persistent inward sodium current, sustained vagal tone, and a cholinergic-like cardiovascular toxidrome[3] |
What unites the members at the chemical level — a non-nitrogenous C20 scaffold built from geranylgeranyl diphosphate — gives no information about what they do in the body. Salvinorin A is notable as the first documented non-nitrogenous natural product with selective high-efficacy agonism at the kappa-opioid receptor, a structural departure from the alkaloid scaffolds that characterize nearly every other known opioid ligand.[1] Grayanotoxin's sodium-channel mechanism is unrelated to opioid signalling at every level.
Because there is no convergent endpoint, the safety logic of the class is also non-shared: each scaffold's risks must be understood on its own terms rather than read off a class-wide profile.
Substances
The brief surfaces three members spanning two scaffold families and two very different roles — a ritual hallucinogen and its plant source, and a cardiovascular toxin encountered incidentally.
| Member | Scaffold / source | Role and distinctive feature |
|---|---|---|
| Salvinorin A | Neoclerodane diterpene; isolated from Salvia divinorum | The first non-nitrogenous natural KOR agonist; short, intense dissociative-hallucinogenic profile |
| Salvia divinorum | Lamiaceae plant; salvinorin A is the active constituent | Ritual plant of the Mazatec people of Oaxaca, Mexico; psychoactivity is essentially that of salvinorin A delivered by leaf or smoke |
| Grayanotoxin | Grayanane diterpene polyol; from Ericaceae (e.g. Rhododendron) | Voltage-gated sodium channel toxin; reaches humans incidentally via "mad honey" |
These members illustrate the diterpene class's defining feature: the same structural label covers compounds whose pharmacological identities have nothing in common. Salvia divinorum and salvinorin A are essentially the same neuroactive entity packaged as plant material versus isolated compound; grayanotoxin sits in a completely different chemical family and is not a substance people seek out for effect.
Subjective Effects
There is no class-wide experiential trajectory. The two scaffolds produce qualitatively different effects, and the appropriate level of generalization is per scaffold rather than per exposure tier.
| Scaffold / member | Characteristic effect profile |
|---|---|
| Neoclerodane — salvinorin A / Salvia divinorum | When inhaled, a rapid-onset hallucinogenic and dissociative state: vivid visual and spatial distortions, depersonalization, derealization, altered body image, loss of motor control, and at times uncontrollable laughter. The peak arrives within roughly two minutes and the experience subsides within about twenty minutes, paralleling the compound's brain pharmacokinetics.[5][6] The character is described as more alien and reality-disrupting than that of classical serotonergic psychedelics, and is often experienced as disorienting rather than pleasurable. |
| Grayanane — grayanotoxin | Initial paresthesia (oral and extremity), nausea, salivation, and dizziness, followed by cardiovascular depression — bradycardia, hypotension, and atrioventricular block — with altered mental status arising from cerebral hypoperfusion rather than direct psychoactivity.[3] The picture is a cholinergic-like toxidrome, not a recreational effect profile. |
Because the two scaffolds reach their effects through unrelated machinery, the same axis does not drive both the desired and the dangerous outcomes across the class — that hinge has to be considered separately for each member.
Safety
Risk profile
The diterpene class does not carry a single shared acute danger; its members reach harm through entirely different routes, and each must be understood on its own terms. Salvinorin A produces a brief but profoundly incapacitating dissociative experience, during which falls, traffic injury, and other environmental harms are the dominant acute risk. Grayanotoxin produces a cholinergic cardiovascular toxidrome — bradycardia, atrioventricular block, hypotension — that can be life-threatening without medical care.
For salvinorin A and Salvia divinorum, the defining hazard is incapacitation during an intense and disorienting state. Onset is so rapid that the user has essentially no time to abort or moderate the experience after inhalation, and there is no pharmacological antidote.[7]
Regulatory toxicology profiles also note serious psychotic disturbances at higher exposures, including lasting psychosis in vulnerable individuals; pre-existing psychotic illness or a strong family history of psychosis is a meaningful risk factor for adverse psychological reactions.[8] The practical harm-reduction measure is supervised setting — a sober sitter and a hazard-free physical environment for the duration of the peak.
For grayanotoxin, the hazard is cardiovascular. Cases are disproportionately associated with imported "mad honey" from the Black Sea region of Turkey and surrounding areas, where Rhododendron-derived honey has long traditional use as a folk medicine.[3]
The toxidrome is generally self-limiting with supportive care and atropine, and most otherwise-healthy adults recover within a few days; severe bradyarrhythmia, however, can be fatal in people with compromised cardiac function or without prompt medical attention.
Tolerance & dependence
The two scaffolds also differ sharply in their dependence profiles, and the class as a whole has no unified tolerance or dependence picture.
Salvinorin A is not known to produce a clinically significant physical withdrawal syndrome. Clinical reviews consistently fail to find the autonomic and craving signs that characterize opioid or sedative dependence.[7][2]
The kappa-opioid mechanism is counter-modulatory rather than classically reinforcing — it suppresses dopamine release in reward circuits and tends to produce aversion rather than euphoria — which is thought to contribute to a self-limiting pattern of use, with many users not repeating the experience.[4]
Rapid functional tolerance (tachyphylaxis) at the kappa-opioid receptor is described in preclinical models, and cross-tolerance to other kappa-opioid agonists is pharmacologically plausible; psychological habituation is reported anecdotally but a formal dependence syndrome has not been established in human studies.
Grayanotoxin is an environmental toxin encountered incidentally, not a substance taken in a repeated pattern, and tolerance, dependence, and withdrawal are not clinically relevant considerations for it.
Recovery
Because no diterpene member produces a life-threatening physical withdrawal syndrome, recovery from problematic use does not require medically supervised detoxification in the way that recovery from alcohol, benzodiazepine, or opioid dependence does.For salvinorin A or Salvia divinorum the work is principally behavioural and psychological — speaking with a clinician, counsellor, or integration-trained therapist is the appropriate first step, particularly where the experience has been distressing or where psychotic symptoms have followed use.
For acute grayanotoxin poisoning the relevant pathway is medical: contact emergency services or a poison control centre, since severe bradycardia and heart block are treatable but require timely supportive care.
Recovery resources, crisis lines, and support pathways → View all
Sub-classes
Members
references
- [1]^abcCunningham, C.W. and Rothman, R.B. and Prisinzano, T.E. (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A — Pharmacological Reviews doi:10.1124/pr.110.003244
- [2]^abCalado S, Pires B, Rosendo LM, Rosado T, Gallardo E, Duarte AP (2025) Salvinorin A and Salvia divinorum: Toxicology, Pharmacological Profile, and Therapeutic Potential — International Journal of Molecular Sciences doi:10.3390/ijms26125588
- [3]^abcdJansen, S.A. and Kleerekooper, I. and Hofman, Z.L.M. and Kappen, I.F.P.M. and Stary-Weinzinger, A. and van der Heyden, M.A.G. (2012) Grayanotoxin Poisoning: 'Mad Honey Disease' and Beyond — Cardiovascular Toxicology doi:10.1007/s12012-012-9162-2
- [4]^abButelman ER, Kreek MJ (2015) Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders — Frontiers in Pharmacology doi:10.3389/fphar.2015.00190
- [5]^Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum — Drug and Alcohol Dependence doi:10.1016/j.drugalcdep.2010.11.005
- [6]^Hooker JM, Xu Y, Schiffer W, Shea C, Carter P, Fowler JS (2008) Pharmacokinetics of the potent hallucinogen, salvinorin A in primates parallels the rapid onset and short duration of effects in humans. — NeuroImage doi:10.1016/j.neuroimage.2008.03.003